Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications

[1]  E. Rummeny,et al.  Low-Dose Gadobenate Dimeglumine Versus Standard Dose Gadopentetate Dimeglumine for Contrast-Enhanced Magnetic Resonance Imaging of the Liver: An Intra-Individual Crossover Comparison , 2003, Investigative radiology.

[2]  R. Günther,et al.  Pancreatic enhancement after low-dose infusion of Mn-DPDP. , 1991, Radiology.

[3]  E. Rummeny,et al.  Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging , 1997, European Radiology.

[4]  R. Lecesne,et al.  Tolerability and utility of mangafodipir trisodium injection (MnDPDP) at the dose of 5 mumol/kg body weight in detecting focal liver tumors: results of a phase III trial using an infusion technique. , 1996, European journal of radiology.

[5]  Jan Grimm,et al.  Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. , 2002, Radiology.

[6]  L. Martí-Bonmatí,et al.  MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers. , 1998, Investigative radiology.

[7]  T. Skotland,et al.  Metabolism and pharmacokinetics of MnDPDP in man , 1997, Acta radiologica.

[8]  H. Weinmann,et al.  A new lipophilic gadolinium chelate as a tissue‐specific contrast medium for MRI , 1991, Magnetic resonance in medicine.

[9]  M. Bernardino,et al.  Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity. , 1992, Radiology.

[10]  R. Edelman,et al.  Hepatic hemangiomas: a multi-institutional study of appearance on T2-weighted and serial gadolinium-enhanced gradient-echo MR images. , 1994, Radiology.

[11]  T. Vogl,et al.  Focal liver lesions: MR imaging with Mn-DPDP--initial clinical results in 40 patients. , 1992, Radiology.

[12]  A. Rahmouni,et al.  Unexpected MR‐T1 enhancement of endocrine liver metastases with mangafodipir , 1999, Journal of magnetic resonance imaging : JMRI.

[13]  M. Choti,et al.  Liver lesions: manganese-enhanced MR and dual-phase helical CT for preoperative detection and characterization comparison with receiver operating characteristic analysis. , 2002, Radiology.

[14]  N. Heaton,et al.  MnDPDP-enhanced MR imaging of the liver , 1997, Acta radiologica.

[15]  H. Ohishi,et al.  Optimal dose of hepatobiliary contrast agent for MR cholangiography: Experimental study in rats , 1998, Journal of magnetic resonance imaging : JMRI.

[16]  T. Murakami,et al.  3DFT‐FISP MRI with Gadopentetate Dimeglumine in Differential Diagnosis of Small Liver Tumors , 1994, Journal of computer assisted tomography.

[17]  A L Baert,et al.  MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: correlation with serologic, microcholangiographic, and histologic findings. , 1994, Radiology.

[18]  C. Bartolozzi,et al.  MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis , 2000, European Radiology.

[19]  A. Rahmouni,et al.  Benign and malignant hepatocellular tumors: evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging , 1999, European Radiology.

[20]  J. Laméris,et al.  MRI with mangafodipir trisodium in the detection and staging of pancreatic cancer , 2000, Journal of magnetic resonance imaging : JMRI.

[21]  C. de Haën,et al.  Soluble‐type hepatobiliary contrast agents for MR imaging , 1993, Journal of magnetic resonance imaging : JMRI.

[22]  V. Lorusso,et al.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. , 1999, Academic radiology.

[23]  S. Hauptmann,et al.  Mn-DPDP in MR imaging of pancreatic adenocarcinoma: initial clinical experience. , 1993, Radiology.

[24]  B. Jenkins,et al.  Gadolinium chelates with weak binding to serum proteins. A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. , 1997, Investigative radiology.

[25]  R. Brasch.  New directions in the development of MR imaging contrast media. , 1992, Radiology.

[26]  Y. Ni,et al.  Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: a correlation study of MR imaging, microangiography, and histology. , 1993, Magnetic resonance imaging.

[27]  G. Schuhmann-Giampieri.  Liver contrast media for magnetic resonance imaging. Interrelations between pharmacokinetics and imaging. , 1993, Investigative radiology.

[28]  G. Marchal,et al.  Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging--a multicenter phase III clinical study. , 2000, Radiology.

[29]  F. Maggioni,et al.  Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) as contrast agent for magnetic resonance imaging of the liver: mechanistic studies in animals. , 1999, Journal of computer assisted tomography.

[30]  M. Mack,et al.  Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. , 1996, Radiology.

[31]  M. Taupitz,et al.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. , 1995, Radiology.

[32]  E. Rummeny,et al.  MRI characteristics in focal hepatic disease before and after administration of MnDPDP: discriminant analysis as a diagnostic tool , 2002, European Radiology.

[33]  P. Robinson,et al.  Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. , 2004, Radiology.

[34]  T. Murakami,et al.  Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP). , 1996, Radiology.

[35]  H. Weinmann,et al.  A toxicologic risk for using manganese complexes? A literature survey of existing data through several medical specialties. , 1995, Investigative radiology.

[36]  F. Schick,et al.  Dynamic MR imaging of liver metastases with Gd-EOB-DTPA , 2000 .

[37]  S. Ekholm,et al.  Diagnostic efficacy of MnDPDP in MR imaging of the liver , 1997, Acta radiologica.

[38]  H. Weinmann,et al.  Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. , 1992, Radiology.

[39]  C. McMahon,et al.  Mn‐DPDP enhancement patterns of hepatocellular lesions on MR images , 1993, Journal of magnetic resonance imaging : JMRI.

[40]  G. Morana,et al.  MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd‐BOPTA) and SPIO (ferumoxides): An intra‐individual comparison , 2003, Journal of magnetic resonance imaging : JMRI.

[41]  K. Linnau,et al.  Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents. , 2002, AJR. American journal of roentgenology.

[42]  K. Ohtomo,et al.  Comparison of Gadobenate Dimeglumine with Gadopentetate Dimeglumine for Magnetic Resonance Imaging of Liver Tumors , 2001, Investigative radiology.

[43]  K. Shamsi.  Gd-EOB-DTPA (EovistO), A Liver Specific Contrast Agent For MRI: Results of a Placebo Controlled, Double Blind Dose Ranging Study in Patients with Focal Hepatic Lesions , 2001 .

[44]  P. Taroni,et al.  Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. , 1998, Academic radiology.

[45]  M Lüning,et al.  Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. , 1994, Radiology.

[46]  G. Morana,et al.  Hypervascular hepatic lesions: dynamic and late enhancement pattern with Gd-BOPTA. , 2002, Academic radiology.

[47]  S. Zangos,et al.  Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient. , 2002, Academic radiology.

[48]  M. Harisinghani,et al.  Contrast‐enhanced MR imaging of the liver: Comparison between Gd‐BOPTA and mangafodipir , 1997, Journal of magnetic resonance imaging : JMRI.

[49]  B. Hamm,et al.  Manganese‐DPDP as a Hepatobiliary Contrast Agent in the Magnetic Resonance Imaging of Liver Tumors: Results of Clinical Phase II Trials in Germany Including 141 Patients , 1991, Investigative radiology.

[50]  M. Kirchin,et al.  Safety assessment of gadobenate dimeglumine (MultiHance®): Extended clinical experience from phase I studies to post‐marketing surveillance , 2001, Journal of magnetic resonance imaging : JMRI.

[51]  F. Schick,et al.  Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. , 2000, Acta radiologica.

[52]  J. Fromkes,et al.  Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan). , 2001, Journal of computer assisted tomography.

[53]  M. Bellin,et al.  Currently used non-specific extracellular MR contrast media , 2003, European Radiology.

[54]  J. Lee,et al.  Differentiation of hepatomas from nonhepatomatous masses: use of MnDPDP-enhanced MR images. , 1994, Magnetic resonance imaging.

[55]  M. Taupitz,et al.  Use of Contrast Agents in the Detection and Differentiation of Focal Liver Lesions by Mr Imaging: Gd-DTPA, Mn-DPDP and Iron Oxide , 1995 .

[56]  M. Taupitz,et al.  Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? , 1997, Radiology.

[57]  P. Reimer,et al.  Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications , 2003, European Radiology.

[58]  M. Kirchin,et al.  Gadobenate dimeglumine (Gd-BOPTA). An overview. , 1998, Investigative radiology.

[59]  M. Saeed,et al.  Gadolinium-Ethoxybenzyl–DTPA, a New Liver-Directed Magnetic Resonance Contrast Agent: Absence of Acute Hepatotoxic, Cardiovascular, or Immunogenic Effects , 1993, Investigative radiology.

[60]  T. Murakami,et al.  Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP). , 1996, Radiology.

[61]  J. Healy,et al.  MnDPDP enhanced magnetic resonance imaging of focal liver lesions. , 2002, Clinical radiology.

[62]  E. Rummeny,et al.  Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. , 1996, Radiology.

[63]  S. Saini,et al.  Comparison of in-phase and out-of-phase gradient recalled echo T1-weighted pulse sequence for MR imaging of malignant liver masses following administration of paramagnetic gadolinium-chelate , 2000, Abdominal Imaging.

[64]  K. Wolf,et al.  Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. , 1994, Radiology.

[65]  A Pfefferbaum,et al.  Hepatobiliary MR imaging: first human experience with MnDPDP. , 1991, Radiology.

[66]  K J Wolf,et al.  Functional hepatobiliary imaging with gadolinium-EOB-DTPA. A comparison of magnetic resonance imaging and 153gadolinium-EOB-DTPA scintigraphy in rats. , 1996, Investigative radiology.

[67]  V. Lorusso,et al.  Hepatic transport of gadobenate dimeglumine in TR-rats. , 1996, Academic radiology.

[68]  C. Claussen,et al.  Mn‐DPDP–enhanced MR imaging of malignant liver lesions: Efficacy and safety in 20 patients , 1993, Journal of magnetic resonance imaging : JMRI.

[69]  W. Schima,et al.  Evaluation of focal pancreatic masses: comparison of mangafodipir-enhanced MR imaging and contrast-enhanced helical CT , 2002, European Radiology.

[70]  C. Colosimo,et al.  Gadobenate dimeglumine‐enhanced magnetic resonance imaging of intracranial metastases: Effect of dose on lesion detection and delineation , 2001, Journal of magnetic resonance imaging : JMRI.

[71]  M. Bernardino,et al.  Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging. , 1993, Radiology.

[72]  W F Bennett,et al.  Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter phase III clinical trials. Efficacy of early imaging , 2000, Journal of magnetic resonance imaging : JMRI.

[73]  S. Kim,et al.  Preoperative detection of hepatocellular carcinoma: ferumoxides-enhanced versus mangafodipir trisodium-enhanced MR imaging. , 2002, AJR. American journal of roentgenology.

[74]  N. Rofsky,et al.  Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy. , 2001, AJR. American journal of roentgenology.

[75]  G. Elizondo,et al.  Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. , 1991, Radiology.

[76]  G. Schuhmann-Giampieri.  Nonlinear pharmacokinetic modeling of a gadolinium chelate used as a liver-specific contrast agent for magnetic resonance imaging. , 1993, Arzneimittel-Forschung.

[77]  P. R. Ros,et al.  Primary liver neoplasms: MR imaging with pathologic correlation. , 1994, Radiographics : a review publication of the Radiological Society of North America, Inc.

[78]  B. V. Van Beers,et al.  Contrast-enhanced MR imaging of the liver. , 1997, Radiology.

[79]  B. Tombach,et al.  Hepatic MRI with SPIO: detection and characterization of focal liver lesions , 1998, European Radiology.